Investment Thesis
Aldeyra Therapeutics is a pre-revenue biopharmaceutical company burning substantial cash with negative operating margins of -35.3M and no commercial revenue generation. While the company maintains adequate liquidity with 70.0M in cash, the current cash burn rate of -33.3M annually suggests only 2+ years of runway, and the complete absence of revenue indicates the company has not yet achieved clinical or commercial success. The negative ROE of -76.5% and deteriorating financial position present significant fundamental concerns.
ALDX Strengths
- Strong liquidity position with 70.0M in cash equivalents
- Conservative leverage with debt-to-equity ratio of 0.35x
- Current ratio of 2.58x indicates ability to meet short-term obligations
ALDX Risks
- No revenue generation - company is entirely pre-commercial
- Substantial ongoing operating losses of -35.3M with negative operating cash flow of -33.3M
- Limited cash runway of approximately 2+ years at current burn rate with no clear path to profitability
- Negative returns on equity (-76.5%) and assets (-47.0%) indicate shareholder value destruction
- Lack of insider purchases (zero Form 4 filings in 90 days) suggests limited confidence from management
Key Metrics to Watch
- Revenue generation timeline and magnitude from clinical development
- Cash burn rate trends and runway extension from partnerships or funding
- Operating expense reduction or clinical trial progression updates
- Debt maturity schedule and refinancing needs
- Insider buying activity as indicator of management confidence
ALDX Financial Metrics
ALDX Profitability Ratios
ALDX Balance Sheet & Liquidity
ALDX 5-Year Financial Trend
5-Year Trend Summary: Aldeyra Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.94 indicates the company is currently unprofitable.
ALDX Growth Metrics (YoY)
ALDX Capital Allocation
ALDX SEC Filings
Access official SEC EDGAR filings for Aldeyra Therapeutics, Inc. (CIK: 0001341235)